Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
WAYNE, Pa. - Teleflex Incorporated (NYSE:TFX) has completed its acquisition of substantially all of BIOTRONIK SE & Co. KG’s Vascular Intervention business for €760 million, the medical technology company announced Tuesday.
The acquisition, which closed earlier than expected, adds a portfolio of therapeutic products to Teleflex’s interventional access offerings and establishes the company’s footprint in the peripheral intervention market. The move comes as the company maintains solid fundamentals with a healthy current ratio of 2.28 and a gross profit margin of 56%.
"The acquisition will significantly enhance our global presence in the cath lab, expand our suite of innovative technologies, and improve patient care," said Liam Kelly, Chairman, President and Chief Executive Officer of Teleflex.
The acquired business includes products for coronary and peripheral interventions performed in cath labs and interventional radiology suites. Key coronary products include the Pantera Lux Drug-Coated Balloon Catheter, PK Papyrus Covered Coronary Stent, and Orsiro Mission Drug Eluting Stent. The peripheral intervention portfolio features the Passeo-18 Lux Peripheral Drug-Coated Balloon Catheter and several stent systems.
Teleflex will also invest in expanding clinical trials for Freesolve, a sirolimus-eluting Resorbable Metallic Scaffold technology that received CE Mark approval in February 2024.
The company expects the acquired products to generate revenues of €177 million ($204 million) in the second half of 2025. Beginning in 2026, Teleflex anticipates annual constant currency revenue growth of 6% or better from these products. According to InvestingPro analysis, the company appears undervalued at current levels, with analysts setting price targets significantly above the current trading price. For detailed valuation metrics and additional insights, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
Excluding non-recurring purchase accounting items and acquisition-related costs, the transaction is expected to add approximately $0.10 to Teleflex’s adjusted earnings per share in the first year of ownership, with increasing accretion thereafter, according to the company’s press release statement.
Teleflex had previously announced its agreement to acquire the business on February 27, 2025.
In other recent news, Teleflex Incorporated reported its Q1 2025 earnings, showing a slight miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of $2.91, falling short of the projected $2.95, and reported revenue of $700.7 million, missing the expected $705.99 million. In addition to the earnings report, Teleflex announced plans to separate into two publicly traded entities, which is intended to enhance shareholder value. The company also completed a $300 million share repurchase program, demonstrating its focus on returning capital to shareholders. Analysts from Morgan Stanley and Jefferies have shown interest in the company’s strategies to mitigate the impact of projected tariffs, which could amount to $55 million. Teleflex remains optimistic about its forward guidance, expecting adjusted constant currency revenue growth of 1% to 2% for 2025. The company is also progressing with the acquisition of BioTronix’s Vascular Intervention business, which is expected to close by the end of Q3 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.